Drugs & Targets Karyopharm submits NDA for Xpovio for relapsed or refractory diffuse large B-cell lymphoma January 03, 2020Vol.46 No.01
Drugs & Targets Amgen and Allergan submit BLA for biosimilar candidate to Rituxan January 03, 2020Vol.46 No.01
Drugs & Targets China approves Zejula as maintenance therapy for recurrent ovarian cancer January 03, 2020Vol.46 No.01
Clinical Roundup NCCN pediatric cancer guidelines focus on improving long-term outcomes worldwide January 03, 2020Vol.46 No.01
Clinical Roundup SWOG study focuses on impact of vitamin and antioxidant supplement use in cancer patients January 03, 2020Vol.46 No.01
Clinical Roundup DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma January 03, 2020Vol.46 No.01
FDA guidance restricts e-cigarette flavors, leaving tobacco and menthol on the market January 03, 2020Vol.46 No.01By Alexandria Carolan and Matthew Bin Han Ong
